To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

Sponsor
Onconic Therapeutics Inc.
Study ID
NCT07370818
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
FEMALE
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • JPI-547 — DRUG
    taking JPI-547
  • Bevacizumab — DRUG
    administration Bevacizumab

Study Details

This study aims to to evaluate the efficacy, safety, and pharmacokinetics of JPI- 547 with bevacizumab maintenance therapy in relapsed ovarian cancer patients

Key Dates

First listed
Jan 27, 2026
Start date
Feb 27, 2026
Status verified
Jan 2026
Primary completion
Dec 31, 2029
Completion
Dec 31, 2031

Study Design

Enrollment
81 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: JPI-547+Bevacizumab
  • Experimental: Bevacizumab

Primary Outcome Measure

Part A: Maximum tolerated dose (MTD) and recommended dose (RD)(RP2D) [ Time Frame: The dose-limiting toxicity evaluation window is 21 days ]

Central Contacts

Related Studies